HCW Biologics Inc. (HCWB) Stock Analysis
A live, multi-source view of HCW Biologics Inc. (HCWB): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Sector: Healthcare · Industry: Biotechnology · United States · 35 employees · hcwbiologics.com
Key statistics · as of 2026-09-05
As of 2026-09-05, HCW Biologics Inc. (HCWB) had a market capitalization of $5.4M (forward -5.3) and a beta of 2.38; the shares traded in a 52-week range of $1.50 – $36.65 (-87.1% over the year).
- Market cap
- $5.4M
- Enterprise value
- $11.2M
- Forward P/E
- -5.3
- Price / book
- 0.64
- EPS (trailing)
- $-16.62
- EPS (forward)
- $-0.55
- Payout ratio
- 0.0%
- 52-week range
- $1.50 – $36.65
- 52-week change
- -87.1%
- Beta
- 2.38
- Average volume
- 137,321
- Shares outstanding
- 1.8M
- Short % of float
- 0.82%
- Profit margin
- -83.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, HCW Biologics Inc. (HCWB) last closed at $2.94 (the last completed close before that scan).
Technicals at the scan: RSI 46 (neutral territory), price +3.5% versus its 20-day average, 20-day versus 50-day average spread -18.2%, MACD histogram 0.12.
Sentiment inputs: StockTwits 100% bullish.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of HCWB; corporate insiders filed 3 buys and 0 sells (3 distinct filers, latest disclosure 2026-07-31). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Lee Flowers (1B/0S), Hing C. Wong (1B/0S), Scott T. Garrett (1B/0S). Who is trading what
RapidTradeView pick record
HCWB has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls HCW Biologics Inc. (HCWB) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell HCWB.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.